CEL-SCI Doesn't OWN multikine!

The Claim

The "Proof"

The "Proof"


 A recent tweet from MG Short said that CEL-SCI doesn't own Multikine. This is so precious. 

He claims that CEL-SCI doesn't own the rights to Multikine. If it was still 1996, he'd be right!  

But let's look at his "proof".

The "Proof"

The "Proof"

The "Proof"


The Short provided redacted documents (above) claiming:

"any commercial products developed by CEL-SCI belong to *redacted*."

Wow. This is concerning. 

Or is it?



A simple internet search was all that was needed to discredit this misrepresentation. 

You see, this is what Shorts do! "Fake News" generally has a kernel of truth.

It WAS true that CEL-SCI didn't own all of the rights prior to March of 1997.

However, in March of 1997, CEL-SCI purchased the rights for Multikine from the Sittona Company (this was the redacted name). 

 The Take-Away: Shorts Lie.  Shorts Misrepresent. Shorts can't be trusted. 


What is multikine?


Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck, and potentially, as a treatment for cervical dysplasia or peri-anal warts in HIV/HPV co-infected patients. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors. Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties and has displayed the following characteristics in studies to date:  

  • Potential first-line treatment: Multikine is administered prior to any other therapy because CEL-SCI believes that this is the period when there is a greater potential likelihood of activating an anti-tumor immune response. Once the patient has had surgery or has received radiation and/or chemotherapy, the immune system may become weakened and may be less able to mount an anti-tumor immune response.
  • Potential to work with the body: Multikine investigational immunotherapy is directed at activating and possibly boosting the body's own anti-tumor immune response to potentially help the body in addressing the tumor.
  • A mixture of different immune molecules, potentially simulating the natural immune system: Multikine is composed of a defined mixture of naturally occurring molecules which in early-phase studies have been reported to be biologically/immunologically active.